Nothing Special   »   [go: up one dir, main page]

WO2024035953A3 - Affinity binding entities directed to psma and methods of use thereof - Google Patents

Affinity binding entities directed to psma and methods of use thereof Download PDF

Info

Publication number
WO2024035953A3
WO2024035953A3 PCT/US2023/030115 US2023030115W WO2024035953A3 WO 2024035953 A3 WO2024035953 A3 WO 2024035953A3 US 2023030115 W US2023030115 W US 2023030115W WO 2024035953 A3 WO2024035953 A3 WO 2024035953A3
Authority
WO
WIPO (PCT)
Prior art keywords
psma
methods
binding entities
affinity binding
entities directed
Prior art date
Application number
PCT/US2023/030115
Other languages
French (fr)
Other versions
WO2024035953A2 (en
WO2024035953A9 (en
Inventor
Blake AFTAB
Arun BHAT
Nitya RAMADOSS
Kevin Nishimoto
Aruna AZAMEERA
Erika Meaddough
Betsy SPELTZ
Alex TEAGUE
Beibei Ding
Original Assignee
Adicet Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Therapeutics, Inc. filed Critical Adicet Therapeutics, Inc.
Publication of WO2024035953A2 publication Critical patent/WO2024035953A2/en
Publication of WO2024035953A9 publication Critical patent/WO2024035953A9/en
Publication of WO2024035953A3 publication Critical patent/WO2024035953A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gynecology & Obstetrics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Aspects of the disclosure include affinity-binding entities that target prostate specific membrane antigen (PSMA), chimeric antigen receptors (CARs) comprising the same, modified immune cells comprising said CARs, and compositions and methods comprising the same for the treatment of conditions associated with PSMA-expression. In embodiments, the modified immune cells are engineered γδ T cells.
PCT/US2023/030115 2022-08-11 2023-08-11 Affinity binding entities directed to psma and methods of use thereof WO2024035953A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263397296P 2022-08-11 2022-08-11
US63/397,296 2022-08-11

Publications (3)

Publication Number Publication Date
WO2024035953A2 WO2024035953A2 (en) 2024-02-15
WO2024035953A9 WO2024035953A9 (en) 2024-03-28
WO2024035953A3 true WO2024035953A3 (en) 2024-04-25

Family

ID=89852457

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/030115 WO2024035953A2 (en) 2022-08-11 2023-08-11 Affinity binding entities directed to psma and methods of use thereof

Country Status (1)

Country Link
WO (1) WO2024035953A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220619A1 (en) * 2023-04-21 2024-10-24 Kite Pharma, Inc. Allogenic therapeutic cells with reduced risk of immune rejection

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470330B2 (en) * 2001-10-23 2013-06-25 Psma Development Company, Llc PSMA antibodies and uses thereof
US10179819B2 (en) * 2015-07-31 2019-01-15 Regeneron Pharmaceuticals, Inc. Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
US20210095047A1 (en) * 2016-11-23 2021-04-01 Harpoon Therapeutics, Inc. PSMA Targeting Trispecific Proteins and Methods of Use
US20210137980A1 (en) * 2018-03-06 2021-05-13 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8470330B2 (en) * 2001-10-23 2013-06-25 Psma Development Company, Llc PSMA antibodies and uses thereof
US10179819B2 (en) * 2015-07-31 2019-01-15 Regeneron Pharmaceuticals, Inc. Anti-PSMA antibodies, bispecific antigen-binding molecules that bind PSMA and CD3, and uses thereof
US20190127480A1 (en) * 2015-07-31 2019-05-02 Regeneron Pharmaceuticals, Inc. Anti-PSMA Antibodies, Bispecific Antigen-Binding Molecules that Bind PSMA and CD3, and Uses Thereof
US20210095047A1 (en) * 2016-11-23 2021-04-01 Harpoon Therapeutics, Inc. PSMA Targeting Trispecific Proteins and Methods of Use
US20210137980A1 (en) * 2018-03-06 2021-05-13 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof

Also Published As

Publication number Publication date
WO2024035953A2 (en) 2024-02-15
WO2024035953A9 (en) 2024-03-28

Similar Documents

Publication Publication Date Title
PH12018500295A1 (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
WO2020092854A3 (en) Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
MX2020010241A (en) Cellular immunotherapy compositions and uses thereof.
ZA202007393B (en) Diverse antigen binding domains, novel platforms and other enhancements for cellular therapy
NZ596022A (en) Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
WO2024035953A3 (en) Affinity binding entities directed to psma and methods of use thereof
WO2020014132A3 (en) Antibodies binding to ilt4
MX2022013466A (en) Ilt-binding agents and methods of use thereof.
WO2009038760A3 (en) Human gm-csf antigen binding proteins
WO2021127200A8 (en) Ilt3-binding agents and methods of use thereof
TW200801041A (en) Antibodies against human IL-22 and uses therefor
EP2332970A3 (en) Mutated pseudomonas exotoxins with reduced antigenicity
WO2021262597A3 (en) Lair-1-binding agents and methods of use thereof
MX2010001363A (en) Immunomodulatory peptides.
WO2019195623A3 (en) Heterodimeric antibodies that bind fibroblast activation protein
PH12020500632A1 (en) Cd83-binding chimerix antigen receptors
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2018169922A3 (en) Chimeric antigen receptors for melanoma and uses thereof
JOP20210011A1 (en) Chimeric receptors to steap1 and methods of use thereof
WO2020070678A3 (en) Antibodies specific for human and cynomolgus apoc3 and methods of use thereof
MX2021011196A (en) Anti-bcma chimeric antigen receptors.
WO2022162518A3 (en) Psma binding proteins and uses thereof
WO2020014505A3 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CR20230245A (en) Gucy2c binding molecules and uses thereof
EP4272822A3 (en) Adamts binding immunoglobulins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23853406

Country of ref document: EP

Kind code of ref document: A2